Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;47(10):1063-1077.
doi: 10.1007/s00134-021-06508-w. Epub 2021 Sep 20.

Critically ill cancer patient's resuscitation: a Belgian/French societies' consensus conference

Anne-Pascale Meert  1 , Sebastian Wittnebel  2 , Stéphane Holbrechts  3 , Anne-Claire Toffart  4 , Jean-Jacques Lafitte  5 , Michael Piagnerelli  6 , France Lemaitre  7 , Olivier Peyrony  8 , Laurent Calvel  9 , Jean Lemaitre  10 , Emmanuel Canet  11 , Alexandre Demoule  12 , Michael Darmon  13 , Jean-Paul Sculier  14 , Louis Voigt  15 , Virginie Lemiale  13 , Frédéric Pène  16 , David Schnell  17 , Etienne Lengline  18 , Thierry Berghmans  19   20 , Laurence Fiévet  19 , Christiane Jungels  19 , Xiaoxiao Wang  19 , Ionela Bold  19 , Aureliano Pistone  19 , Adriano Salaroli  2 , Bogdan Grigoriu  14 , Dominique Benoit  21 ; Critically ill cancer patients consensus conference group
Collaborators, Affiliations

Critically ill cancer patient's resuscitation: a Belgian/French societies' consensus conference

Anne-Pascale Meert et al. Intensive Care Med. 2021 Oct.

Abstract

To respond to the legitimate questions raised by the application of invasive methods of monitoring and life-support techniques in cancer patients admitted in the ICU, the European Lung Cancer Working Party and the Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique, set up a consensus conference. The methodology involved a systematic literature review, experts' opinion and a final consensus conference about nine predefined questions1. Which triage criteria, in terms of complications and considering the underlying neoplastic disease and possible therapeutic limitations, should be used to guide admission of cancer patient to intensive care units?2. Which ventilatory support [High Flow Oxygenation, Non-invasive Ventilation (NIV), Invasive Mechanical Ventilation (IMV), Extra-Corporeal Membrane Oxygenation (ECMO)] should be used, for which complications and in which environment?3. Which support should be used for extra-renal purification, in which conditions and environment?4. Which haemodynamic support should be used, for which complications, and in which environment?5. Which benefit of cardiopulmonary resuscitation in cancer patients and for which complications?6. Which intensive monitoring in the context of oncologic treatment (surgery, anti-cancer treatment …)?7. What specific considerations should be taken into account in the intensive care unit?8. Based on which criteria, in terms of benefit and complications and taking into account the neoplastic disease, patients hospitalized in an intensive care unit (or equivalent) should receive cellular elements derived from the blood (red blood cells, white blood cells and platelets)?9. Which training is required for critical care doctors in charge of cancer patients?

Keywords: Cancer; Critically ill; Haematological; ICU.

PubMed Disclaimer

Conflict of interest statement

APM declares having received grant from BMS outside the submitted work. DB reports grants from Gilead, Astellas, Fisher-Paykel, Baxter, Alexion and Fresenius Kabi outside the submitted work. ACT reports grants, personal fees and non-financial support from Roche, personal fees and non-financial support from Astra Zeneca, personal fees and non-financial support from BMS, personal fees and non-financial support from MSD, grants, personal fees and non-financial support from Pfizer, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Vifor Pharma, personal fees and non-financial support from Novartis, personal fees from Amgen, outside the submitted work. EC received fees from Gilead and Sanofi Aventis for lectures and transport accommodation. AD reports personal fees from Medtronic, grants, personal fees and non-financial support from Philips, personal fees from Baxter, personal fees from Hamilton, personal fees and non-financial support from Fisher and Paykel, grants from French Ministry of Health, personal fees from Getinge, grants and personal fees from Respinor, grants and non-financial support from Lungpacer, outside the submitted work. MD declares having recieved speaker fees from Astelas, Gilead and MSD and declare having received a research grant from MSD. VL is treasorier of research group who received fee from Pfizer, Fisher-Paykel, Gilead, Astellas, Alexion. FP received institutional grant from ALEXION PHARMA. JP Sculier none.

References

    1. Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B, Marcos-Gragera R, Maynadie M, Monnereau A, Osca-Gelis G, Visser O, De Angelis R, E.-W. Group Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15(9):931–942. doi: 10.1016/S1470-2045(14)70282-7. - DOI - PubMed
    1. Durocher A, Carpentier F, Dosquet P. A methodology for consensus conferences. Societe Royale Belge de Gastro-enterologie, Acta Gastroenterol Belg. 1998;61(4):416–421. - PubMed
    1. Shimabukuro-Vornhagen A, Boll B, Kochanek M, Azoulay E, von Bergwelt-Baildon MS. Critical care of patients with cancer. CA Cancer J Clin. 2016;66(6):496–517. doi: 10.3322/caac.21351. - DOI - PubMed
    1. Azoulay E, Mokart D, Pene F, Lambert J, Kouatchet A, Mayaux J, Vincent F, Nyunga M, Bruneel F, Laisne LM, Rabbat A, Lebert C, Perez P, Chaize M, Renault A, Meert AP, Benoit D, Hamidfar R, Jourdain M, Darmon M, Schlemmer B, Chevret S, Lemiale V. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en reanimation onco-hematologique study. J Clin Oncol. 2013;31(22):2810–2818. doi: 10.1200/JCO.2012.47.2365. - DOI - PubMed
    1. Gruson D, Vargas F, Hilbert G, Bui N, Maillot T, Mayet T, Pillet O, Chene G, Gbikpi-Benissan G. Predictive factors of intensive care unit admission in patients with haematological malignancies and pneumonia. Intensive Care Med. 2004;30(5):965–971. doi: 10.1007/s00134-004-2237-1. - DOI - PubMed

Publication types